Intra-Cellular Therapies, Inc.
Industry
- Biotechnology
- Drug Discovery Technologies
- Pharmaceuticals
- Vaccines
Latest on Intra-Cellular Therapies, Inc.
Johnson & Johnson is the first big pharma to report first quarter sales and earnings, and thus the first to outline expectations about the impact of tariffs on its financial outlook. So far, J&
Merger-and-acquisition activity in the biopharmaceutical sector had almost nowhere to go but up in the first quarter of 2025, following a historically low quarter in terms of total potential deal valu
Two companies of similar economic scale and each with its own troubled financial history revealed plans to merge on 13 March, as privately held Mallinckrodt and publicly traded Endo will combine into
Entering 2025, biopharma industry observers expected an uptick of merger-and-acquisition activity, coming off a 2024 that saw some historic lows for such activity. Hopes were raised with some sizeab